{"title":"艾滋病2010——第十八届国际艾滋病大会。","authors":"Belete A Desimmie","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The AIDS 2010-XVIII International AIDS Conference, held in Vienna, included topics covering new therapeutic developments in the field of HIV therapy. This conference report highlights selected presentations on novel HIV entry inhibitors, reverse transcriptase inhibitors, integrase inhibitors and clinical trial data for an NRTI-based, antiviral, hyperactivation-limiting therapeutic. Investigational drugs discussed include GSK-1349572 (Viiv Healthcare/Shionogi & Co Ltd) and VS-411 (ViroStatics).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"622-5"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AIDS 2010--XVIII International AIDS Conference.\",\"authors\":\"Belete A Desimmie\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The AIDS 2010-XVIII International AIDS Conference, held in Vienna, included topics covering new therapeutic developments in the field of HIV therapy. This conference report highlights selected presentations on novel HIV entry inhibitors, reverse transcriptase inhibitors, integrase inhibitors and clinical trial data for an NRTI-based, antiviral, hyperactivation-limiting therapeutic. Investigational drugs discussed include GSK-1349572 (Viiv Healthcare/Shionogi & Co Ltd) and VS-411 (ViroStatics).</p>\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 9\",\"pages\":\"622-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在维也纳举行的2010- 18届艾滋病国际会议的主题包括艾滋病毒治疗领域的新治疗发展。本次会议报告重点介绍了新型HIV进入抑制剂、逆转录酶抑制剂、整合酶抑制剂和基于nrti的抗病毒、超激活限制治疗的临床试验数据。讨论的研究药物包括GSK-1349572 (Viiv Healthcare/Shionogi & Co Ltd)和VS-411 (virostatic)。
The AIDS 2010-XVIII International AIDS Conference, held in Vienna, included topics covering new therapeutic developments in the field of HIV therapy. This conference report highlights selected presentations on novel HIV entry inhibitors, reverse transcriptase inhibitors, integrase inhibitors and clinical trial data for an NRTI-based, antiviral, hyperactivation-limiting therapeutic. Investigational drugs discussed include GSK-1349572 (Viiv Healthcare/Shionogi & Co Ltd) and VS-411 (ViroStatics).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
